

## Macular Degeneration Guideline Committee – development

**Date:** Wednesday 13<sup>th</sup> July

**Location:** NICE offices, Manchester

**Minutes:** Final

<b>Committee members present:</b>	
Waqar Shah (Chair)	Present for all items
Katy Barnard (KB)	Present for all items
Nick Beare (NB)	Present for all items
Cathie Burke (CB)	Present for all items
Jennifer Evans (JE)	Present from item 3
Alexander Foss (AF)	Present for all items
Mary Freeman (MF)	Present for all items
Carol McCletchie (CM)	Present for all items
Elizabeth Wick (EW)	Present for all items
Cathy Yelf (CY)	Present for all items

<b>In attendance:</b>	
Louisa Crossley (LC) NICE – Senior Medicines Advisor	Present for all items
Francesca Fasesin (FF) NCG Research Fellow	Present for all items
Andreas Freitag (ANF) NCG Senior Research Fellow	Present for all items
Chris Gibbons (CG) ICG – Technical Analyst (HE)	Present for all items
Vonda Murray (VM) ICG – Project Manager	Present for all items
Gabriel Rogers (GR)	Present for all items

## Macular Degeneration Guideline Committee 8 minutes

ICG – Technical Advisor (HE)	
Yingying Wang (YW) ICG – Technical Analyst	Present for all items

<b>Observers:</b>	
Jackie Durkin ICG – Administrator	Present until partway through item 2
Jamie Elvidge ICG – Technical Analyst (HE)	Present from item 4
Judith Hughes PhD student	Present for all items
Patrick Langford NICE – Technical Analyst	Present for all items

<b>Apologies:</b>	
Sue Ellerby (SE)	ICG – Clinical Advisor
Andy Charley	Committee member
Caroline Keir	NICE – Guideline Commissioning Manager
Dave Nicholls	NICE – Information Specialist
Ellen Rule	Committee member
Mary-Ann Sherratt	Committee member
Sue Spiers	NICE – ICG, Associate Director

## 1. Introductions, apologies, minutes, DOI and objectives for the meeting

The Chair welcomed the Committee members, attendees and observers to the 8th meeting on age-related macular degeneration (AMD). The committee members, attendees and observers introduced themselves.

Apologies were noted, as recorded above.

The Chair invited each attendee to declare any new conflicts since the previous meeting. The following conflicts were noted;

Attendee	Declaration	Action
MF	Contribution to a publication on the identification, diagnosis and prompt treatment of diabetic macular oedema (DMO). The publication is supported by Bayer. The publication will be non-drug related and will not have any specific recommendations relating to drug choice. An honorarium has been paid.	Declare and participate

Having reviewed all previous and new declarations of interest it was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The minutes were reviewed from GComm 7; 24/05/2016. One correction was noted;

- Page 1, attendance, update the table to bring consistency to wording used.

Subject to the amendment noted above the minutes were agreed to be an accurate record.

### **VM to update the minutes**

The Chair provided a brief overview of the objectives for the day highlighting the information that would be discussed.

### **2. RQ15 What is the effectiveness of switching therapies for neovascular AMD if the first-line therapy is contraindicated or has failed?**

- **Presentation of clinical evidence**
- **Agree evidence statements**

FF presented the evidence regarding the effectiveness of switching therapies for neovascular AMD if the first-line therapy is contraindicated or has failed?

### **3. RQ11 What are the indicators for treatment failing and switching?**

#### **RQ14 What factors indicate that treatment for neovascular AMD should be stopped?**

- **Presentation of clinical evidence**
- **Agree evidence statements**
- **Draft recommendations**

FF presented the evidence for;  
What are the indicators for treatment failing and switching?  
What factors indicate that treatment for neovascular AMD should be stopped?

The committee discussed the evidence provided for RQ11, RQ14 and RQ15. Based on the evidence presented and their own clinical experience and expertise the committee made recommendations and research recommendations.

## LUNCH

### **4. RQ17 What are the barriers and facilitators to appointment attendance and uptake of treatment for people with AMD?**

- **Draft recommendations**

YW led a discussion with the committee around the evidence that was presented at the previous meeting. The recommendations were reviewed and developed further.

### **5. Health Economics update**

CG Presented an update on model development work and asked the group to confirm the key assumptions needed to parameterize the model. Also agreed the ways in which data on effectiveness of drug treatments can be rationalized to improve the connectedness of the NMA feeding into the economic model. The group discussed and provided input, particularly with regards to how doses and frequencies of different anti-VEGF agents could be grouped.

### **6. RQ7 What is the effectiveness of strategies to reduce the risk of developing AMD in the unaffected eye or slow the progression of AMD?**

- **Presentation of clinical evidence**
- **Agree evidence statements**
- **Draft recommendations**

YW presented an overview of the evidence for, what is the effectiveness of strategies to reduce the risk of developing AMD in the unaffected eye or slow the progression of AMD? YW presented clinical evidence on the effectiveness of antioxidant vitamin and mineral supplements on AMD progression. The evidence was discussed by the committee. CG presented two economic evaluations to the group on high dose vitamin therapies.

## Macular Degeneration Guideline Committee 8 minutes

Presentation of evidence and discussion of other strategies to reduce the risk of AMD progression will continue at the next meeting.

### **7. AOB**

None

### **8. Summary and next steps**

The Chair thanked the committee for their time and contribution to the meeting. The venue, date and time of the next meeting was confirmed.

Date of next meeting: GDG 9 - Monday 5th & Tuesday 6th September 2016

Location of next meeting: NICE offices, Manchester